Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423187 | 0.84 | MEN1 (0.64) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL29897636 | 0.84 | MEN1 (0.64) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL19100943 | 0.83 | ALDH1A1 (0.51) | AHRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5824244 | 0.83 | ALDH1A1 (0.47) | AHRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL3518634 | 0.82 | ALDH1A1 (0.46) | AHRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL7563419 | 0.82 | SMN1; SMN2 (0.49) | RAB9ANPC1ALDH1A1TP53LMNA | |
| SCHEMBL22056715 | 0.82 | ALDH1A1 (0.46) | AHRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5211841 | 0.82 | MEN1 (0.47) | AHRMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL13849276 | 0.81 | AHR (0.47) | AHRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5198021 | 0.81 | RAB9A (0.65) | AHRRAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239165-A1 | PHENYLSULFONAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-12-14 | — | — | WO | disclosed |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4161928-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115515960-A | Aminopyrimidine cyclic amides | 豪夫迈·罗氏有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022256680-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ATRIN PHARMACEUTICALS (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021249904-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021249904-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| WO-2011083316-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011083316-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | QDPR, P2RY1, REN | AHR 419/4885RAB9A 1611/4885NPC1 1072/4885 |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | ATXN2, ATXN2L, ATXN10 | AHR 426/4885RAB9A 1899/4885NPC1 4047/4885 |
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ARAF, BRAF, RAF1 | AHR 1644/4885RAB9A 569/4885NPC1 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.